Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPA | P23025 | 10/20 | 0.60 |
| ▸ | EP300 | Q09472 | 2/20 | 0.57 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | APEX1 | P27695 | 2/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
| ▸ | GALK1 | P51570 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12900113 | 0.93 | CLEC4M (0.65) | XPAEP300CLEC4MGSK3AMEN1 | |
| SCHEMBL445806 | 0.93 | CLEC4M (0.65) | XPAEP300CLEC4MGSK3AMEN1 | |
| SCHEMBL445808 | 0.93 | CLEC4M (0.65) | XPAEP300CLEC4MGSK3AMEN1 | |
| SCHEMBL446574 | 0.83 | GSK3A (0.62) | XPAEP300GSK3AMEN1KMT2A | |
| SCHEMBL420800 | 0.83 | GSK3A (0.62) | XPAEP300GSK3AMEN1KMT2A | |
| SCHEMBL446576 | 0.83 | GSK3A (0.62) | XPAEP300GSK3AMEN1KMT2A | |
| SCHEMBL445262 | 0.82 | CLEC4M (0.79) | XPAEP300CLEC4MMEN1KMT2A | |
| SCHEMBL420952 | 0.82 | CLEC4M (0.79) | XPAEP300CLEC4MMEN1KMT2A | |
| SCHEMBL445263 | 0.82 | CLEC4M (0.79) | XPAEP300CLEC4MMEN1KMT2A | |
| SCHEMBL19652472 | 0.79 | GSK3A (0.79) | XPAEP300GSK3AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | XPA 4857/4885EP300 3876/4885CLEC4M 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.